Longevity Optimization: Evidence-Based Protocols for Healthspan Extension
Last reviewed: August 2026
Longevity optimization is the deliberate application of evidence-based interventions to extend healthspan — the period of life spent in full physical and cognitive capability — not just lifespan. The distinction matters: living to 95 while spending the last 15 years in managed decline is not optimization. The goal is compressing morbidity: staying functional longer, declining faster only at the very end.
What the evidence actually supports
Four interventions carry human evidence strong enough that arguing about them is no longer interesting. They are unglamorous, they are free or nearly free, and they account for the overwhelming majority of the modifiable variance in how long you stay capable.
VO2 max
Cardiorespiratory fitness is the strongest single modifiable predictor of all-cause mortality in the observational literature, and the dose-response does not appear to plateau. Moving from the bottom quartile to above average is associated with a larger risk reduction than eliminating smoking or hypertension. Three to four hours of easy aerobic work weekly plus one session of hard intervals is the protocol. Training science.
Resistance training
Muscle mass is longevity insurance. Sarcopenia begins in the fourth decade and accelerates, and grip strength independently tracks with mortality and with the ability to stay independent after seventy. Two to four progressive sessions a week with adequate protein is the only reliable countermeasure. Strength protocol.
Sleep
Consolidation, glymphatic clearance and HRV recovery all depend on sleep, and all degrade measurably without it. Chronic short sleep impairs glucose control within days and is associated with elevated cardiovascular and neurodegenerative risk over decades. Sleep protocol.
Metabolic health
Fasting insulin, ApoB and hs-CRP are the primary biomarkers, and they move earlier than the diagnoses they predict. Visceral fat, glycemic control and lipoprotein burden are the mechanism through which most of the preventable disease burden arrives.
If you did nothing else — trained aerobically, lifted twice a week, slept seven to nine hours and kept those three markers in range — you would capture most of what is currently available to capture. Everything past this point is refinement.
What doesn't yet have strong evidence
The interesting part of the field is also the part with the weakest human data. None of the following is dismissed here; each is simply not yet at the standard where it belongs ahead of the fundamentals.
NMN and NR supplementation
Raising NAD+ levels in tissue is a mechanistically attractive idea and the rodent data are genuinely interesting. Human trials to date show that oral precursors reliably raise blood NAD+ metabolites — and then largely fail to show the downstream functional benefits that would justify the price. Promising, insufficient.
Rapamycin
The most credible small-molecule candidate for slowing aging biology, and also the one with the most meaningful risk. There is no consensus on dose, interval, or who benefits, and immunosuppression at the wrong schedule is not a theoretical concern. This is an off-label decision to make with a physician who has read the literature, not a supplement.
Senolytics
Clearing senescent cells rejuvenates function in animal models to a degree that is difficult to ignore. Human trials are early, small, and mostly focused on specific disease states rather than healthy aging. The concept may well survive; the current consumer protocols are ahead of the evidence.
The general longevity supplement stack
Most of what is sold under the longevity label is either a nutrient you would get from adequate diet, a compound with mouse-only data, or a dose too low to do anything. The opportunity cost is real: money and attention spent here is money and attention not spent on training, sleep and lab work.
Educational only. Nothing here is medical advice. Off-label compounds, hormone therapy and prescription interventions require a licensed physician who has reviewed your labs and history.
The five biomarkers to start with
A hundred-marker panel is a way to feel productive without changing anything. Five markers, tested twice a year and acted on, will move your risk curve further than a full-body scan you never repeat.
1. ApoB
The count of atherogenic particles in circulation, and the most actionable cardiovascular number you can measure. LDL cholesterol estimates the cargo; ApoB counts the vehicles, and the vehicle count is what drives arterial wall infiltration. It responds to diet, to exercise, and — when it needs to — to medication.
2. Fasting insulin
Insulin resistance shows up here years before glucose or HbA1c move, which is exactly why it is worth measuring and exactly why it is rarely ordered. A fasting insulin in the high single digits with normal glucose is an early warning that the pancreas is compensating.
3. HbA1c
A three-month average of glucose regulation. Less sensitive than fasting insulin for early dysfunction, but it is cheap, standardized, and it captures the trend that matters over years rather than the reading you happened to take on a bad morning.
4. hs-CRP
A crude but useful proxy for systemic inflammation. Persistently elevated hs-CRP in the absence of acute illness tracks with cardiovascular and all-cause risk, and it frequently improves when sleep, visceral fat and training load are brought back into range.
5. VO2 max estimate
Functional capacity in a single number. A lab test is ideal, but a wearable estimate or a submaximal field test is directionally useful and gives you something to move. It is the only item on this list that is also a training target.
Use the same lab and, where possible, the same assay each time. Between-lab variation on fasting insulin in particular is large enough to manufacture trends that do not exist. Compare lab testing services if you do not already have a provider, or see the Function Health review for the broadest annual panel.
For a full comparison of lab testing services to run these biomarkers — Function Health, Marek Health, Hone and direct-to-consumer options — see the lab testing comparison.
Why personalization matters
A longevity protocol for a 35-year-old with optimal metabolic health looks completely different from one for a 52-year-old with insulin resistance and poor sleep architecture. The interventions are the same — the sequencing and priority are not.
For the first person, the binding constraint is usually aerobic base and consistency: they can afford to spend a year building VO2 max and strength without touching diet composition much at all. For the second, sleep and glycemic control come first, because training adaptation is blunted while both are broken — adding volume to an under-slept, insulin-resistant system produces fatigue rather than fitness.
The practical rule: fix the input that is most out of range before optimizing the one that is already adequate. Most people invert this, adding a supplement stack to a six-hour sleep schedule.
The Performance Protocol longevity stack
The full programme — training structure, nutrition targets, recovery scaffolding and the testing calendar — lives in the main protocol. Start there once you know which of the five markers is furthest from where it should be.
Frequently asked questions
What is longevity optimization?
Longevity optimization is the deliberate application of evidence-based interventions to extend healthspan — the period of life spent in full physical and cognitive capability — rather than lifespan alone. In practice it means measuring a small set of biomarkers, changing training, sleep and nutrition against them, and re-measuring. The goal is compressing morbidity: staying functional longer and declining faster only at the very end.
What interventions have the best evidence for longevity?
Four carry the strongest human evidence: raising VO2 max, maintaining muscle mass through resistance training, protecting seven to nine hours of sleep, and keeping metabolic markers — fasting insulin, HbA1c and ApoB — in a healthy range. The observational and trial data behind these dwarf the evidence base for rapamycin, senolytics or NAD precursors in healthy humans.
What biomarkers should I track for longevity optimization?
Start with five: ApoB for atherosclerotic risk, fasting insulin for early insulin resistance, HbA1c for three-month glycemic control, hs-CRP for systemic inflammation, and an estimated VO2 max for functional capacity. Those five cover the leading causes of both death and functional decline, and all can be obtained cheaply.
What is the difference between lifespan and healthspan?
Lifespan is total years lived. Healthspan is the number of years lived without significant chronic disease or functional decline. In most developed countries the gap between the two is roughly a decade. Optimizing for healthspan means training and testing so that the final years are a short decline rather than a long managed one.
Is longevity optimization worth it?
The high-evidence portion is unambiguously worth it: fitness, muscle, sleep and metabolic health improve how you feel this year as well as your risk curve over decades. The speculative portion — unproven compounds, expensive scans, supplement stacks marketed on mouse data — has a much weaker return and often substitutes for the boring interventions that actually work.
Written by
John Stewart — Founder, Performance Protocol
John is an operator with two decades of experience building and leading performance-driven teams. He is not a physician. Performance Protocol exists because he needed a system for training, recovery, hormones, and cognitive output that was built on data rather than marketing — and could not find one.
Every protocol on this site references peer-reviewed research, with full citations listed on each page so claims can be verified at the source.
LinkedIn profile